Table 3

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Nisreen M.A. Okba¹, Marcel A. Müller¹, Wentao Li¹, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, Reina S. Sikkema, Erwin de Bruin, Felicity D. Chandler, Yazdan Yazdanpanah, Quentin Le Hingrat, Diane Descamps, Nadhira Houhou-Fidouh, Chantal B.E.M. Reusken, Berend-Jan Bosch, Christian Drosten, Marion P.G. Koopmans, and Bart L. Haagmans

Author affiliations: Erasmus Medical Center, Rotterdam, the Netherlands (N.M.A. Okba, C.H. GeurtsvanKessel, M.M. Lamers, R.S. Sikkema, E. deBruin, F.D. Chandler, C.B.E.M. Reusken, M.P.G. Koopmans, B.L. Haagmans); Charité-Universitätsmedizin Berlin, Berlin, Germany (M.A. Müller, V.M. Corman, C. Drosten); German Centre for Infection Research, Berlin (M.A. Müller, V.M. Corman, C. Drosten); Utrecht University, Utrecht, the Netherlands (W. Li, C. Wang, B.-J. Bosch); Université de Paris, Paris, France (Y. Yazdanpanah, Q. Le Hingrat, D. Descamps); Hôpital Bichat-Claude Bernard, Paris (Y. Yazdanpanah, Q. Le Hingrat, D. Descamps, N. Houhou-Fidouh); RIVM, Bilthoven, the Netherlands (C.B.E.M. Reusken)

Main Article

Correlations between ODs/OD ratios and PRNT results of 10 serum samples obtained from 3 PCR-confirmed COVID-19 patients from France and tested in Rotterdam, the Netherlands, 6–27 d after diagnosis*

Test, virus	Correlations	In-house ELISAs					Euroimmun ELISAs
Test, virus	Correlations	S1	N	RBD	S	S1A	IgA	IgG
PRNT₅₀, SARS-CoV-2	Spearman ρ value	0.87	0.94	0.92	0.94	0.93	0.98	0.92
	2-tailed p value	0.0021	0.0002	0.0005	0.0002	0.0003	<0.0001	0.0005
	p value summary	<0.01	<0.001	<0.001	<0.001	<0.001	<0.0001	<0.001
PRNT₉₀, SARS-CoV-2	Spearman ρ value	0.88	0.88	0.88	0.88	0.88	0.93	0.88
	2-tailed p value	0.0024	0.0024	0.0024	0.0024	0.0024	0.0008	0.002
	p value summary	<0.01	<0.01	<0.01	<0.01	<0.01	<0.001	<0.01

*COVID-19, coronavirus disease 2019; OD, optical density; N, nucleocapsid; PRNT₅₀, 50% plaque reduction neutralization test; PRNT₉₀, 90% plaque reduction neutralization test; RBD, receptor-binding domain; S, spike; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

¹These authors contributed equally to this article.

Page created: April 08, 2020

Page updated: June 18, 2020

Page reviewed: June 18, 2020

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.